Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease

Neuropharmacology ◽

10.1016/j.neuropharm.2018.02.012 ◽

2018 ◽

Vol 133 ◽

pp. 385-394 ◽

Cited By ~ 35

Author(s):

Peng Feng ◽

Xiangjian Zhang ◽

Dongfang Li ◽

Chenhui Ji ◽

Ziyue Yuan ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Mouse Model ◽

Receptor Agonists ◽

Gip Receptor

Download Full-text

The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease

Journal of Parkinson s Disease ◽

10.3233/jpd-191768 ◽

2020 ◽

Vol 10 (2) ◽

pp. 523-542 ◽

Cited By ~ 9

Author(s):

Lingyu Zhang ◽

Liping Zhang ◽

Yanwei Li ◽

Lin Li ◽

Josefine Ulrikke Melchiorsen ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Receptor Agonist ◽

The Novel ◽

Receptor Agonists ◽

Mptp Model ◽

Gip Receptor

Download Full-text

Serotonin 5-HT4 receptor agonists improve facilitation of contextual fear extinction in an MPTP-induced mouse model of Parkinson's disease

Proceedings for Annual Meeting of The Japanese Pharmacological Society ◽

10.1254/jpssuppl.93.0_1-p-033 ◽

2020 ◽

Vol 93 (0) ◽

pp. 1-P-033

Author(s):

Toshiaki Ishii ◽

Yoshikage Muroi

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Mouse Model ◽

Fear Extinction ◽

Contextual Fear ◽

Receptor Agonists

Download Full-text

Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models

Neuropharmacology ◽

10.1016/j.neuropharm.2018.01.040 ◽

2018 ◽

Vol 136 ◽

pp. 251-259 ◽

Cited By ~ 54

Author(s):

Christian Hölscher

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Disease Models ◽

Neuroprotective Effects ◽

Receptor Agonists ◽

Gip Receptor

Download Full-text

Neuronal nicotinic receptor agonists ameliorate spontaneous motor asymmetries and motor discoordination in a unilateral mouse model of Parkinson's disease

Pharmacology Biochemistry and Behavior ◽

10.1016/j.pbb.2013.07.005 ◽

2013 ◽

Vol 111 ◽

pp. 1-10 ◽

Cited By ~ 12

Author(s):

Aaron Kucinski ◽

Scott Wersinger ◽

Ewa K. Stachowiak ◽

Thomas D. Corso ◽

Matthew J. Parry ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Mouse Model ◽

Nicotinic Receptor ◽

Neuronal Nicotinic Receptor ◽

Receptor Agonists ◽

Motor Asymmetries

Download Full-text

Diffusion kurtosis imaging detects a very early α-synuclein accumulation induced changes in transgenic mouse model of parkinson’s disease overexpressing α-synuclein

10.26226/morressier.5785edc7d462b80296c994db ◽

2016 ◽

Author(s):

Anas Arab

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Mouse Model ◽

Transgenic Mouse ◽

Transgenic Mouse Model ◽

Diffusion Kurtosis Imaging ◽

Induced Changes ◽

Diffusion Kurtosis

Download Full-text

Faculty Opinions recommendation of Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.733700001.793551488 ◽

2018 ◽

Author(s):

Vladimir Uversky

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Mouse Model ◽

Cell Loss ◽

Synapsin Iii

Download Full-text

ERK/MAP Kinase Activation is Evident in Activated Microglia of the Striatum and Substantia Nigra in an Acute and Chronically-Induced Mouse Model of Parkinson’s Disease

Current Neurovascular Research ◽

10.2174/1567202616666181123152601 ◽

2019 ◽

Vol 15 (4) ◽

pp. 336-344 ◽

Cited By ~ 5

Author(s):

Sumit Sarkar ◽

Edward Lu ◽

James Raymick ◽

Joseph Hanig ◽

Qiang Gu

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Substantia Nigra ◽

Mouse Model ◽

Map Kinase ◽

Kinase Activation ◽

Activated Microglia

Download Full-text

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Journal of Medicinal Chemistry ◽

10.1021/acs.jmedchem.1c00303 ◽

2021 ◽

Author(s):

Xiang-Li Ning ◽

Yu-Zhi Li ◽

Cui Huo ◽

Ji Deng ◽

Cheng Gao ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Mouse Model ◽

Guided Discovery ◽

X Ray ◽

Orally Bioavailable

Download Full-text

Diabetes, insulin and new therapeutic strategies for Parkinson’s disease: focus on glucagon-like peptide-1 receptor agonists

Frontiers in Neuroendocrinology ◽

10.1016/j.yfrne.2021.100914 ◽

2021 ◽

pp. 100914

Author(s):

Carmen M. Labandeira ◽

Arturo Fraga-Bau ◽

David Arias Ron ◽

Ana Muñoz ◽

Gema Alonso-Losada ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Therapeutic Strategies ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Disease Focus

Download Full-text

Repurposing GLP-1 Receptor Agonists for Parkinson’s Disease: Current Evidence and Future Opportunities

Pharmaceutical Medicine ◽

10.1007/s40290-020-00374-5 ◽

2021 ◽

Author(s):

Daniella Balduino Victorino ◽

Mariana Nejm ◽

Marcia Guimarães-Marques ◽

Fulvio Alexandre Scorza ◽

Carla Alessandra Scorza

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Current Evidence ◽

Receptor Agonists

Download Full-text